Fairvalue-Calculator Fairvalue-Calculator
EN DE

Cosmax, Inc (192820) Fair Value & Analysis

Consumer Defensive · KR · Market cap 1.9T KRW

Price152,500 KRW
Fair Value218,255 KRW
Upside+43.1%
Quality91/100
Evidence: Medium Range 152,779 KRW – 284,729 KRW

Analysis

Cosmax, Inc (192820) currently trades at 152,500 KRW, while our model-based Fair Value estimate is 218,255 KRW — implying the stock looks roughly 43.1% undervalued today. We read business quality at 91/100 (high quality), in the Consumer Defensive sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

About the company

Cosmax, Inc. researches, develops, produces, and manufactures cosmetic and health function food products in Korea and internationally. The company operates through Cosmetic Business segment, Custom Cosmetic, and other Business segments. The company offers skincare products under the Capsule+, IS-LCE, CeraPresso, Emulixir, Foamology, IRPT, and Solar Clear brands; base-make up under the Air Cloud, and skin fabric names; and make up under the Xfine, JellTeX, ARTCOTTA, Bi-Coat, creamline, Thixolash, and CRYSTAL PRISM brands; oriental medicine under the Ginsenology name; and fragrance under the Scenteritage brand, as well as hair care products. The company was formerly known as Miroto Korea and changed its name to Cosmax, Inc. in 1994. Cosmax, Inc. was founded in 1992 and is headquartered in Hwaseong-si, South Korea.

Open the full interactive analysis →

Similar stocks

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.